Puma Biotechnology (PBYI) Enterprise Value (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Enterprise Value came in at -$38.3 million in Q1 2026, up 58.91% YoY from -$24.1 million in Q1 2025, and down 20.67% on a QoQ basis from -$31.7 million in Q4 2025.
Puma Biotechnology (PBYI) Enterprise Value (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Enterprise Value data on file, last reported at -$38.3 million in Q1 2026.
- Quarterly Enterprise Value rose 58.91% year-over-year to -$38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$38.3 million (up 58.91% YoY) and the FY2025 annual result came in at -$31.7 million, up 68.58% from the prior year.
- Enterprise Value eased to -$38.3 million in Q1 2026, from -$31.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$31.7 million in Q4 2025 to a low of -$107.2 million in Q1 2024.
- A 5-year average of -$78.0 million and a median of -$81.1 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 50.47% — and 2025, when it soared 68.58%.
- Tracing PBYI's Enterprise Value over 5 years: stood at -$81.1 million in 2022, then retreated by 18.34% to -$95.9 million in 2023, then fell by 5.24% to -$101.0 million in 2024, then soared by 68.58% to -$31.7 million in 2025, then decreased by 20.67% to -$38.3 million in 2026.
- The last three Enterprise Value figures came in at -$38.3 million (Q1 2026), -$31.7 million (Q4 2025), and -$94.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | -93.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -93.90 Mn |
| Mar 31, 2026 | -38.28 Mn |
| Dec 31, 2025 | -31.73 Mn |
| Sep 30, 2025 | -94.39 Mn |
| Jun 30, 2025 | -56.75 Mn |
| Mar 31, 2025 | -93.17 Mn |
| Dec 31, 2024 | -100.97 Mn |
| Sep 30, 2024 | -96.73 Mn |
| Jun 30, 2024 | -96.83 Mn |
| Mar 31, 2024 | -107.16 Mn |
| Dec 31, 2023 | -95.94 Mn |
| Sep 30, 2023 | -85.03 Mn |
| Jun 30, 2023 | -74.44 Mn |
| Mar 31, 2023 | -71.22 Mn |
| Dec 31, 2022 | -81.07 Mn |
| Sep 30, 2022 | -77.96 Mn |
| Jun 30, 2022 | -60.75 Mn |
| Mar 31, 2022 | -63.91 Mn |
| Dec 31, 2021 | -71.98 Mn |
| Sep 30, 2021 | -87.54 Mn |